Varex Imaging
NASDAQ: VREX
$10.92 ▲ +0.00  (+0.00%)
At close: Jul 27, 2026 · 2:54 PM UTC
Financial Ratios
Market Cap457.59 Mn
P/E-5.55
P/S0.53
Div. Yield0.00
ROIC (Qtr)-0.02
Total Debt (Qtr)366.20 Mn
Revenue Growth (1y) (Qtr)1.46
Add ratio to table…

About

Varex Imaging Corporation designs manufactures and sells X ray imaging components and systems for medical security and industrial applications. The company produces X ray tubes flat panel and photon counting detectors high voltage connectors image processing software workstations and related accessories. Its products are incorporated into original equipment manufacturer systems that serve computed tomography mammography cardiac surgery dental fluoroscopy and other diagnostic…

Read more ↓
Sector: Healthcare Industry: Medical Devices CIK: 0001681622

Investment Thesis

▲ Bull case
  • Varex Imaging is positioned to benefit significantly from the accelerating adoption of photon counting technology across multiple imaging modalities beyond CT, with eight active OEM engagements in non-CT applications such as CBCT, DR, and breast imaging. Management emphasized that full-body photon counting CT remains the company's largest long-term market opportunity, and while two CT OEM customers are making steady progress toward commercialization aligned with 2029 goals, the broadening engagement across modalities indicates a diversified pipeline that could drive earlier-than-expected recurring revenue streams. This expansion reduces reliance on a single modality and positions VREX to capture value as OEMs seek differentiation through advanced imaging capabilities, particularly as AI integration increases demand for high-quality, preprocessed image data directly at the detector level. The company's tube and smart detector technologies enable preprocessing that supports Agentic AI applications, addressing radiologist shortages in emerging markets—a structural tailwind not fully reflected in current guidance.
  • The India manufacturing ramp, while currently a headwind to gross margins and operating expenses due to low utilization, represents a structural cost advantage in the making. Detector factory utilization is expected to reach 60%-70% by year-end, with gradual approval-driven ramp, and once achieved, will create meaningful margin tailwinds through lower labor and production costs. Management explicitly framed the current impact as a temporary headwind that will reverse into a tailwind upon crossing utilization thresholds, and the tube factory's ongoing facilitization phase suggests additional capacity is being built for future scaling. This dual-track ramp in India not only de-risks supply chain concentration but also supports long-term gross margin expansion independent of near-term revenue growth, offering a leveraged upside to profitability as utilization inflects upward.
  • Cargo security systems are demonstrating sustained momentum with multiple new deals booked across various countries, including mobile inspection systems and car scanners, signaling broadening adoption beyond traditional fixed installations. Management expressed strong visibility into the pipeline, noting well-distributed bookings from new prospects, geographies, and products, and highlighted that installations are progressing as anticipated. This business, while lumpy and tender-driven, is becoming an increasingly significant driver of Industrial segment growth and margin expansion, with Industrial Services already contributing to gross margin expansion by offsetting inflationary cost increases. The reacceleration in cargo security orders, combined with ongoing implementation driving temporary inventory buildup, points to a deferred revenue recognition tailwind that could bolster second-half performance as acceptance procedures conclude and revenue converts from backlog.
▼ Bear case
  • Varex Imaging faces persistent structural headwinds in EMEA, where revenue declined 16% year-over-year, driven by the lapping of a large linear accelerator order from a European-based customer in the prior year. Management acknowledged that industrial revenue for linear accelerators was exceptionally strong in fiscal 2025 due to this single customer's large order, and the current year-over-year comparison reflects a natural trough in a lumpy, project-based business. While security inspection systems are gaining traction in EMEA, they have not yet offset the decline from the lapsed linear accelerator business, creating a revenue gap that management did not adequately address when discussing overall Industrial segment growth. This reliance on episodic large orders introduces volatility that is not fully mitigated by diversification efforts, and the segment's growth remains dependent on winning infrequent, high-value tenders rather than consistent recurring demand.
  • Inventory buildup remains a material and underappreciated risk, with days of inventory increasing to 220—up six days sequentially—and a $19 million quarter-over-quarter rise to $347 million. While management attributed this to temporary factors including cargo system implementations and India ramp-related raw material transfers, the scale of the increase suggests deeper inefficiencies in demand forecasting or supply chain alignment. The company's target to reduce inventory by $20 million–$25 million in coming quarters is ambitious given the concurrent ramp of two new manufacturing facilities in India, which requires sustained raw material and work-in-process investment. Failure to achieve this reduction would tie up working capital, increase storage and obsolescence risks, and constrain free cash flow generation, particularly as net debt leverage stands at 2.2x trailing twelve-month adjusted EBITDA, leaving limited buffer for further working capital deterioration.
  • The noncash mark-to-market charge of $1.8 million related to the Micro-X equity investment, which management confirmed is not adjusted out of non-GAAP metrics, continues to distort profitability metrics and may recur if Micro-X's share price remains volatile. This charge directly impacted GAAP net loss ($8 million) and GAAP EPS ($0.19 loss), creating a divergence between GAAP and non-GAAP performance that could erode investor trust if perceived as recurring or inadequately disclosed. More critically, the decision not to adjust this charge suggests a reluctance to isolate core operational performance, raising concerns about transparency in how management presents earnings quality. In an environment where investors scrutinize adjusted metrics for sustainability, this policy could lead to multiple compression if the market begins to question the reliability of VREX's reported non-GAAP earnings as a proxy for true operational earnings power.

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 ABT Abbott Laboratories 183.48 Bn29.244.0734.05 Bn
2 SYK Stryker Corp 129.11 Bn38.695.1114.72 Bn
3 MDT Medtronic plc 108.35 Bn22.402.9827.96 Bn
4 BSX Boston Scientific Corp 68.68 Bn19.263.3311.03 Bn
5 EW Edwards Lifesciences Corp 48.35 Bn2,346.887.670.60 Bn
6 DXCM Dexcom Inc 28.38 Bn30.505.89-
7 GEHC GE HealthCare Technologies Inc. 28.04 Bn14.191.3410.14 Bn
8 SNN Smith & Nephew Plc 26.92 Bn161.234.193.18 Bn